Lilly disses Amgen and Mirati as it debuts new KRAS molecule
Eli Lilly is rejoining the KRAS hunt.
The Indianapolis Big Pharma revealed Thursday, in an abstract for AACR, that it has been working on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
